Saeed Sadeghi, MD
Dr. Saeed Sadeghi is interested in clinical trials, as a principal investigator or sub-investigator, in the area of breast and hepatobiliary cancer novel therapies.
Khaledy C, Ashouri S, Hiyama D, Sadeghi S. Trastuzumab based Neoadjuvant Chemotherapy for Locally Advanced HER2 Over Expressing Gastric Adenocarcinoma. Proceedings of UCLA Healthcare 17: 1-4, 2013.
Tsang RY, Sadeghi S, Finn RS. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of Egfr and Her2, in Her2-Amplified Breast Cancer: From Bench to Bedside. Clinical Medicine Insights: Therapeutics 3: 1-13, 2011.
Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. doi: 10.1200/JCO.2010.28.5437. Epub 2011 Sep 12.
Sadeghi S, Wong SG. Targeting Angiogenesis in Ovarian Cancer, a brief review of Literature. Proceedings of UCLA Healthcare 15: 1-4, 2011.
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.